Gastroenterology
1115 articles · 33 journals
Publication dynamics
Journals in this subcategory (33)
- Alimentary Pharmacology and Therapeutics · Wiley (87)
- Clinical Gastroenterology and Hepatology · Elsevier (86)
- iGIE · Elsevier (85)
- Journal of Gastrointestinal Surgery · Elsevier (75)
- Digestive and Liver Disease · Elsevier (72)
- Revista de Gastroenterología de México · Elsevier (69)
- Gastro Hep Advances · Elsevier (60)
- Hepatobiliary & Pancreatic Diseases International · Elsevier (60)
- ESMO Gastrointestinal Oncology · Elsevier (58)
- Arab Journal of Gastroenterology · Elsevier (57)
- Best Practice & Research Clinical Gastroenterology · Elsevier (54)
- Gastrointestinal Endoscopy Clinics of North America · Elsevier (52)
- Asian Journal of Endoscopic Surgery · Wiley (47)
- Clinical Colorectal Cancer · Elsevier (44)
- Clinics and Research in Hepatology and Gastroenterology · Elsevier (41)
- Gastroenterology Clinics of North America · Elsevier (37)
- Annals of Gastroenterological Surgery · Wiley (34)
- Journal of Gastrointestinal Surgery Open · Elsevier (30)
- Digestive Endoscopy · Wiley (20)
- Colorectal Disease · Wiley (19)
- Journal of Digestive Diseases · Wiley (12)
- United European Gastroenterology Journal · Wiley (10)
- JGH Open · Wiley (6)
- BMC Gastroenterology · Springer Nature (0)
- Clinical Journal of Gastroenterology · Springer Nature (0)
- Current Gastroenterology Reports · Springer Nature (0)
- Current Treatment Options in Gastroenterology · Springer Nature (0)
- Digestive Diseases and Sciences · Springer Nature (0)
- Esophagus · Springer Nature (0)
- Gastric Cancer · Springer Nature (0)
- Indian Journal of Gastroenterology · Springer Nature (0)
- International Journal of Colorectal Disease · Springer Nature (0)
- Journal of Gastroenterology · Springer Nature (0)
- DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial
- Age-stratified mutation patterns in early-onset colorectal cancer reveal distinct molecular features and therapeutic implications☆
- Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
- Adjuvant treatment of gastrointestinal stromal tumors (GIST)—state of the art, controversies, and future directions
- Assessing the relationship between event-free and overall survival in randomized controlled trials of perioperative chemoimmunotherapy in gastroesophageal cancers
- Risk factors for second primary esophageal cancer after head and neck squamous cell carcinoma: a systematic review and meta-analysis
- Dynamic HER2 reassessment and precision sequencing after trastuzumab in HER2-positive advanced gastric cancer
- Claudin 18.2 expression—concordance between primary and metastatic lesions in gastric and gastroesophageal adenocarcinomas: a systematic review and meta-analysis
- Early-onset adenocarcinomas of the distal esophagus, gastroesophageal junction, and stomach: a systematic review and meta-analysis of 45 studies
- RAS-targeted therapies for pancreatic cancer
- Sex-based survival differences in patients with untreated advanced oesophageal squamous cell carcinoma receiving chemotherapy and immune checkpoint inhibitors: a meta-analysis
- Recent advances in loco-ablative therapies for liver cancers
- Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials☆
- Dual versus single-agent immune checkpoint inhibitor therapy in microsatellite instability-high metastatic colorectal cancer: an analysis based on reconstructed patient data
- Prognostic relevance of secondary actionable fusions in MLH1-deficient dMMR/MSI-H gastrointestinal tumors treated with pembrolizumab
- Strategies to overcome barriers in access to cancer treatment in Latin America: a regional perspective
- Microsatellite instability testing in gastrointestinal cancers: current standards, challenges and future directions
- Expanding the ESMO-MCBS: integrating organ preservation into clinical benefit assessment in rectal cancer
- TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes
- Care delivery among patients with early-onset versus average-onset cholangiocarcinoma: a nationwide retrospective analysis
- Patterns of presentation and diagnostic delays in biliary tract cancers: a real-world European study
- Consensus recommendations for the management of locally advanced rectal cancer
- Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study
- Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy
- Real-world outcomes of first-line gemcitabine–platinum plus an immune checkpoint inhibitor and subsequent treatment with matched targeted therapy in biliary tract cancer
- Comprehensive characterisation of patients with colorectal cancer and permanently liver-limited disease
- Differences in treatment and outcomes between young and older patients with colorectal cancer liver metastases: an AmCORE-based study
- Transarterial chemoembolization combined with immunotherapy-based treatments versus TACE alone in unresectable hepatocellular carcinoma: a systematic review and network meta-analysis
- Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors
- Reprogramming the tumor microenvironment in MSS CRC: the role of TKIs in combination with immunotherapy